Title : Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.

Pub. Date : 2013 Jan

PMID : 23211422






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. Platinum KRAS proto-oncogene, GTPase Homo sapiens